We are live on ! Find out more
SFAM

Springhill Fund Asset Management Portfolio holdings

AUM $20.9M
This Fund
S&P 500
This Quarter Est. Return
+8.77%
1 Year Est. Return
–
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$20.9M
AUM Growth
-$40.7M
Cap. Flow
-$44.1M
Cap. Flow %
-211.32%
Top 10 Hldgs %
82.88%
Holding
30
New
13
Increased
2
Reduced
4
Closed
11

Top Buys

Rank Stock Value
1
SMMT icon
Summit Therapeutics
SMMT
+$2.49M
2
JANX icon
Janux Therapeutics
JANX
+$1.84M
3
REGN icon
Regeneron Pharmaceuticals
REGN
+$1.79M
4
NBIX icon
Neurocrine Biosciences
NBIX
+$1.72M
5
JAZZ icon
Jazz Pharmaceuticals
JAZZ
+$1.29M

Top Sells

Rank Stock Value
1
LEGN icon
Legend Biotech
LEGN
+$6.21M
2
CYTK icon
Cytokinetics
CYTK
+$6.15M
3
AKRO
Akero Therapeutics
AKRO
+$5.56M
4
AZN icon
AstraZeneca
AZN
+$5.01M
5
VERA icon
Vera Therapeutics
VERA
+$4.63M

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
VRNA
1
DELISTED
Verona Pharma
VRNA
$4.03M 19.32%
63,499
-71,953
-53% -$4.3M
SMMT icon
2
Summit Therapeutics
SMMT
$10.2B
$2.4M 11.49%
+124,307
New +$2.49M
JANX icon
3
Janux Therapeutics
JANX
$912M
$2.12M 10.16%
78,500
+48,900
+165% +$1.84M
REGN icon
4
Regeneron Pharmaceuticals
REGN
$72.9B
$1.65M 7.9%
+2,600
New +$1.79M
NBIX icon
5
Neurocrine Biosciences
NBIX
$18.2B
$1.51M 7.21%
+13,612
New +$1.72M
INSM icon
6
Insmed
INSM
$22.4B
$1.46M 7.02%
19,192
-50,308
-72% -$3.85M
SLNO
7
DELISTED
Soleno Therapeutics
SLNO
$1.42M 6.8%
19,858
+18,065
+1,008% +$880K
JAZZ icon
8
Jazz Pharmaceuticals
JAZZ
$16.1B
$1.22M 5.86%
+9,853
New +$1.29M
AKRO
9
DELISTED
Akero Therapeutics
AKRO
$807K 3.87%
19,925
-131,275
-87% -$5.56M
ARGX icon
10
argenx
ARGX
$55.2B
$678K 3.25%
+1,146
New +$723K
LLY icon
11
Eli Lilly
LLY
$1.08T
$674K 3.23%
+816
New +$679K
PTGX icon
12
Protagonist Therapeutics
PTGX
$8.55B
$622K 2.98%
+12,859
New +$539K
TGTX icon
13
TG Therapeutics
TGTX
$8.19B
$532K 2.55%
+13,500
New +$454K
TARS icon
14
Tarsus Pharmaceuticals
TARS
$2.55B
$363K 1.74%
+7,076
New +$350K
ASND icon
15
Ascendis Pharma A/S
ASND
$16.5B
$339K 1.62%
+2,173
New +$310K
RYTM icon
16
Rhythm Pharmaceuticals
RYTM
$7.31B
$332K 1.59%
+6,277
New +$348K
BNTX icon
17
BioNTech
BNTX
$23.5B
$273K 1.31%
+3,000
New +$336K
SWTX
18
DELISTED
SpringWorks Therapeutics
SWTX
$260K 1.25%
+5,897
New +$271K
COGT icon
19
Cogent Biosciences
COGT
$6.76B
$177K 0.85%
29,491
-519,063
-95% -$4.07M
ABVX
20
Abivax
ABVX
$10.4B
– –
-207,600
Closed -$1.52M
AZN icon
21
AstraZeneca
AZN
$269B
– –
-38,250
Closed -$5.01M
BCYC
22
Bicycle Therapeutics
BCYC
$269M
– –
-116,400
Closed -$1.63M
CGEM icon
23
Cullinan Oncology
CGEM
$1.06B
– –
-276,400
Closed -$3.37M
CYTK icon
24
Cytokinetics
CYTK
$10.6B
– –
-130,735
Closed -$6.15M
DRUG
25
Bright Minds Biosciences
DRUG
$697M
– –
-60,648
Closed -$2.18M
1
2

Similar funds

FGN
Foundry Group Next Boulder, Colorado $21.1M AUM 35.51% 1-Year Est. Return
NTIMCH
New Thinking Investment Management Company (HK) Hong Kong $20.4M AUM 4.24% 1-Year Est. Return
CJL
Cyrus J. Lawrence New York $26.4M AUM 16.63% 1-Year Est. Return
GDCML
Galaxy Digital Capital Management LP New York $13.5M AUM
TC
Tarsadia Capital New York $5.64M AUM 15.7% 1-Year Est. Return
OWP
Old Well Partners Charlotte, North Carolina $4.55M AUM 27.75% 1-Year Est. Return
MECA
Miller Equity Capital Advisors Irving, Texas $1.45M AUM 7.67% 1-Year Est. Return
SC
Spinnaker Capital Boston, Massachusetts $1.08M AUM 45.28% 1-Year Est. Return

Springhill Fund Asset Management's Q1 2025 Portfolio in Review

As of Q1 2025, Springhill Fund Asset Management held 30 positions worth $20.9M, down 66% from $61.6M the previous quarter. Its ten largest holdings account for 83% of the portfolio.

Springhill Fund Asset Management withdrew a net $44.1M in Q1 2025, closing 11 positions and reducing 4 holdings. Its most notable exit was Legend Biotech, an estimated $6.21M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.

Against the trend, Springhill Fund Asset Management opened a new position in Summit Therapeutics worth $2.4M.

  • Springhill Fund Asset Management's largest Q1 2025 buy was Summit Therapeutics: 124,307 shares worth $2.4M.
  • Springhill Fund Asset Management added most to Janux Therapeutics in Q1 2025, an estimated $1.84M increase.
  • Springhill Fund Asset Management's biggest Q1 2025 reduction was Akero Therapeutics, cutting an estimated $5.56M.
  • Springhill Fund Asset Management fully exited Legend Biotech in Q1 2025, selling an estimated $6.21M.
  • Springhill Fund Asset Management's ten largest holdings make up 83% of its $20.9M portfolio in Q1 2025.
  • Springhill Fund Asset Management opened 13 new positions and closed 11 in Q1 2025.
  • Springhill Fund Asset Management's portfolio value fell 66% quarter-over-quarter to $20.9M.

Based on Springhill Fund Asset Management's 13F filing for Q1 2025, filed 14 May 2025.